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readmissions).
General comment: the paper could benefit from a more detailed description of key methodological issues, like pharmacological interventions, further justification of posology to be tested, which is outside product labelling recommendations and against relevant guidelines (not only in relationship to treatment duration, but also with respect to the timing of first administration), and measures to minimize bias at the time of adjudicating the events, given that this is an open label trial. In addition, further trials designs could benefit from a more rigorous methodology, and in line with current revision of the EMA guideline in this indication (EMA/CHMP/325170/2012).
Specific comments:
1) "Background": the purpose of using different posologies in terms of timing of first dose and treatment duration from that recommended in the product labelling and widely accepted VTE guidelines (NICE Guideline CG92; ACCP Guideline, 2012) should be further justified. The justification should cover not only the decision to give 42 days of prophylaxis, instead of the recommended 10-14 days, but also the decision to start all medications 6 after surgery. Current recommendations in guidelines and product labelling include: dabigatran etexilate, starting 1-4 hours after surgery; rivaroxaban, starting 6-10 hours after surgery; Nadroparin, started 12 hours before surgery. There are several papers suggesting that the delay in the timing of first administration of the anticoagulant may provide some benefits in bleeding and potential decrease in risk of spinal hematoma, but this benefit does not outweigh the increase in thrombotic events.
2) Related to previous issue, one of the aims of further studies would be if the nonadherence to dosing recommendations, as tested in DARINA, would provide some benefit compared to the administration of the medications in accordance to product labelling.
3) Section "interventions": The authors should describe the timing of first administration of each anticoagulant as well as the dose to be administered. 4) Section "interventions". Triggers for blood transfusion should be clearly defined in the study protocol given that one criterion for major bleeding is the need for transfusion. This issue may significantly impact major bleeding rates. 5) "Measurements" section: reference 21 is out of date (see comment 8a) and main and secondary outcomes should be clearly specified. In the abstract it seems that the main outcome is the composite of major and clinically relevant non-major bleeding. However, in "measurements" section, it seems that the main outcome is knee function.
6) "Randomization" section. In this section should be specified if the orthopaedic surgeon who follows the patients, measures functional knee range of motion, collect primary information about bleeding events and decides if confirmatory tests for VTE are performed is aware of treatment assignment or not. 7) Sample size calculation. It is unfortunate that the study has not included a formal calculation of sample size, or an estimation of the number of patients that will withdraw the study prematurely. With respect to detect differences in bleeding endpoints (major and clinically relevant non-major bleeding) the sample size seems insufficient. According to a recent meta-analysis with more than 38,000 patients analysed, differences in clinically relevant bleeding between rivaroxaban and enoxaparin were about 0.9% and in indirect comparisons between dabigatran and rivaroxaban were about 0.5% [Gomez-Outes et al, BMJ 2012; 344:e3675] . Probably the DARINA study should have been focused in a more sensitive bleeding endpoint (see also comment 8a). As a result, the probability a false negative due to lack of statistical power is significant.
8) The following documents are to be taken into account at the time of designing a large-scale multicentre confirmatory clinical trial and/or implemented in current study if possible:
8a) The EMA guideline on clinical investigation in this indication (Ref. 21 of the manuscript) is being revised, and will be replaced by the following publicly available draft guideline: Clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery (EMA/CHMP/325170/2012). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/0 5/WC500127902.pdf This guideline already recognises the need for standardisation of bleeding definitions and gives standardised definitions of major and clinically relevant bleeding (previous guideline did not include a definition of clinically relevant non-major bleeding, despite authors used this guideline to reference their definition). In addition the revised guideline recommends the following secondary bleeding-related endpoints that are more sensitive to detect differences in blood loss: Laboratory parameters: haemoglobin plasma level, haematocrit and red cell count changes during the treatment period, Operative blood loss (mL) quantified by an objective method (weight of swabs and operative drapes, volumes in the suction bottles after surgery). Post-operative wound drainage (mL) quantified by and objective method (drain collectors on admission to the post-anaesthesia care unit and thereafter for the two postoperative days). Patients with post-operative drain (n, %) Calculated blood loss (peri-operative, postoperative) using the following formula: Calculated bleeding, expressed in ml of red blood cells (RBC), haematocrit (Ht) 100% = estimated blood volume (EBV) x (preoperative Ht -day 2 Ht) + 150 ml per RBC or cell salvage unit, assuming an EBV of 70 ml/kg (men) or 65 ml/kg (women) and, respectively, 65 ml/kg and 60 ml/kg for obese men and women. Bleeding index (mean, ±SD) calculated in each patient as the number of units of packed red cells or whole blood transfused plus the haemoglobin values prerandomisation minus the haemoglobin values at the end of treatment period. Patients with bleeding index ≥ 2 at the end of treatment period relative to haemoglobin pre-randomisation levels (n, %). Patients receiving transfusion of packed red cells (n, %) (homologous and autologous transfusions need to be distinguished). Transfusion volume (mL; mean, ±SD) and transfusion units (U; mean, ±SD) during the treatment period (homologous and autologous transfusions need to be distinguished).
8b) The Xamos phase IV study, which compares rivaroxaban versus enoxaparin, may give an idea of what is the expected difference in symptomatic events with these compounds in current in standard practise: Turpie et al. 
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THE STUDY
My main comment is that the authors should consider testing the feasibility of using a PROBE design. The haemorrhagic outcomes could be independently adjudicated by blinded observers, as could the VTE scans. Otherwise, the open-label nature means that preconceptions about particular treatments could bias the diagnosis of bleeds or VTE.
Other minor comments: 1) How will haemorrhage be detected and classified once the patient is out of hospital? There is potential loss to follow-up here.
2) Are the coagulation tests for rivaroxaban or dabigatran validated? 3) I couldn't quite see the purpose of the knee assessment scores.
REPORTING & ETHICS
It might help if the protocol was structured in such a way that most of the CONSORT checklist was addressed, this would help the authors prepare a full trial report in future.
VERSION 1 -AUTHOR RESPONSE
Reviewer Dr Mike Holmes Most good quality trials nowadays collect generic quality of life data using instruments such as the EQ5D. This is important because many countries have a system where health interventions are assessed for cost-effectiveness. Having access to EQ5D data means that all interventions can be compared to each other. The KOOS data will allow comparisons with all knee interventions and that may be useful. However, it may be a lost opportunity if you do not collect generic quality of life data in your main study.
Reply: Thank your for your advice. The EQ5D will be included in the multicenter trial. We have now described the use of the EQ5D in the Discussion section, see page 9 of 15.
Reviewer Dr. Antonio Gómez-Outes The purpose of using different posologies in terms of timing of first dose and treatment duration from that recommended in the product labelling and widely accepted VTE guidelines (NICE Guideline CG92; ACCP Guideline, 2012) should be further justified. The justification should cover not only the decision to give 42 days of prophylaxis, instead of the recommended 10-14 days, but also the decision to start all medications 6 after surgery. Current recommendations in guidelines and product labelling include: dabigatran etexilate, starting 1-4 hours after surgery; rivaroxaban, starting 6-10 hours after surgery; Nadroparin, started 12 hours before surgery. There are several papers suggesting that the delay in the timing of first administration of the anticoagulant may provide some benefits in bleeding and potential decrease in risk of spinal hematoma, but this benefit does not outweigh the increase in thrombotic events.
Reply:
We have included a discussion on the posology, timing and duration of the prophylaxis in the Backgroud section, see page 3 of 15. Different guidelines exist for the prevention of venous thromboembolism in orthopaedic surgery. Previous surveys in the Netherlands have revealed that guidelines for orthopaedic thromboprophylaxis were not followed and that a wide variation in protocols exists. Of the 84% of included orthopaedic departments in the Netherlands, 78% used prophylaxis with LMWH. In these hospitals, 85% continued prophylaxis for 42 days.16 Also, a short survey revealed that duration of DVT prophylaxis in knee replacement surgery remained 42 day in a large share of the hospitals (approximately 80%) in the Netherlands. In order to prevent deviations in medication quality and safety in medication administration, all three study medication will be administered within 6 hours after TKA. The dose to be administered and the time of first administration of study medication will be registered.
Related to previous issue, one of the aims of further studies would be if the non-adherence to dosing recommendations, as tested in DARINA, would provide some benefit compared to the administration of the medications in accordance to product labelling.
Reply: Thank you for your suggestion. We will include this in the design of our further investigations.
Section "interventions": The authors should describe the timing of first administration of each anticoagulant as well as the dose to be administered.
Reply: Postoperatively, the patient receives the allocated thromboprophylaxis. Patients will take either a daily oral dose of dabigatran etexilate (2 capsules of 110 mg) 220 mg (n=50) starting with a half-dose (110 mg) 6 hours after surgery (n=50) during 42 days, or 10 mg of oral rivaroxaban once daily, starting 6 hours after surgery during 42 days, or daily subcutaneous nadroparin 2850 IE/ml, 0.3 ml starting 6 hours after surgery during 42 days. The administered dose and the time of first administration will be registered. Please, see page 7 of 15 for the revised text.
Section "interventions". Triggers for blood transfusion should be clearly defined in the study protocol given that one criterion for major bleeding is the need for transfusion. This issue may significantly impact major bleeding rates.
Triggers for blood transfusion are clearly defined in the Dutch CBO guideline: Blood transfusion (containing criteria for major bleeding and the need for transfusion), see the inserted reference number 27. In hospital guidelines for blood transfusion triggers were derived from the national guideline. In short, below a Hb of 4 mmol/l (6.4 g/dL) is always indicated, above 6 mmol/l (9.7 g/dL) only in rare cases. Between 4 and 6 mmol/l transfusion is based on the clinic of the patient. We have now included these triggers in the text, see page 8 of 15.
"Measurements" section: reference 21 is out of date (see comment 8a) and main and secondary outcomes should be clearly specified. In the abstract it seems that the main outcome is the composite of major and clinically relevant non-major bleeding. However, in "measurements" section, it seems that the main outcome is knee function.
We have clarified the outcomes by bringing more structure in the outcomes, see page 8 and 9. First we describe the main outcomes, than the secondary outcomes and lastly the additional outcomes.
"Randomization" section. In this section should be specified if the orthopaedic surgeon who follows the patients, measures functional knee range of motion, collect primary information about bleeding events and decides if confirmatory tests for VTE are performed is aware of treatment assignment or not.
The orthopaedic surgeon is aware of the treatment assignment we have now clarified this on page 6 of 15.
Point 7, 8, 8a and 8b
Reply: Thank you for your suggestions and comments which undoubtedly are very useful for the planning of our future investigations. Reviewer Dr. Yoon K. Loke My main comment is that the authors should consider testing the feasibility of using a PROBE design. The haemorrhagic outcomes could be independently adjudicated by blinded observers, as could the VTE scans. Otherwise, the open-label nature means that pre-conceptions about particular treatments could bias the diagnosis of bleeds or VTE. The haemorrhagic outcomes could be independently adjudicated by blinded observers, as could the VTE scans.
We have checked the PROBE design. The blinding of the information and the blinded evaluation by the end-point committee are crucial. Therefor we we have now clarified this on:
Randomisation page 8: After closure of the clinical trial a blinded committee will adjudicate bleeding events independently by classifying the observed bleeding using information provided by the orthopaedic surgeon and the patient, as described in table 2.
Measurements, bleeding assessment page 8: Any bleeding events that occur perceived by patient, researcher, nurse, orthopaedic surgeon or other health worker will be registered and defined. A blinded committee will adjudicate bleeding events independently by classifying the description and pictures taken of the observed bleeding.
How will haemorrhage be detected and classified once the patient is out of hospital? There is potential loss to follow-up here.
Patients are informed about the possibility to contact their orthopaedic surgeon or researcher about any adverse events they experience during or after the treatment with the anticoagulant (in the home situation). On day 4 up until 6 after discharge the patients will be contacted daily by a orthopaedic nurse. Bleeding events that occur in the home situation will all be registered, there will not be loss to follow up. Additionally, patients will be seen at the regular check six weeks after surgery at the outpatient clinic.
Are the coagulation tests for rivaroxaban or dabigatran validated?
Reply: Coagulation monitoring will be performed by measuring anti-Xa activity, activated partial thromboplastin time (aPTT), protrombine time (PT) and two validated clotting assays developed to measure the anticoagulant activity of rivaroxaban and dabigatran. A validation report is available on request. See page 8.
I couldn't quite see the purpose of the knee assessment scores.
Reply: KOOS evaluates the functional status and quality of life of patients with any type of knee injury. Therefore we want to measure the clinical condition of patients before and after treatment, to see if there is any difference in knee function and quality of life between the treatment groups, nadroparin, rivaroxaban or dabigatran. We assume that there will be a relation between clinical relevant (non)-major bleeding and knee function. Above note will be mentioned in the protocol. See page 7 of 15.
Reply: Thank you for your suggestion, we have changed the structure of the protocol.
